Idarubicin, ara-c, and topotecan in patients with refractory or relapased acute myelogenous leukemia and high-risk myelodysplastic syndrome.

被引：0
|
作者：
Min, YH [1 ]
Jang, JH [1 ]
Lee, ST [1 ]
Hahn, JS [1 ]
Ko, YW [1 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4251
引用
收藏
页码：234B / 234B
页数：1
相关论文
共 50 条
  • [1] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee, ST
    Hahn, JS
    Ko, YW
    Min, YH
    BLOOD, 2001, 98 (11) : 215B - 215B
  • [2] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome
    Lee, ST
    Jang, JH
    Suh, HC
    Hahn, JS
    Ko, YW
    Min, YH
    AMERICAN JOURNAL OF HEMATOLOGY, 2001, 68 (04) : 237 - 245
  • [3] Extended study for topotecan, idarubicin, and intermediate-dose cytarabine combination chemotherapy in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Kim, Y
    Cheong, JW
    Kim, JS
    Park, IH
    Park, SY
    Lee, ST
    Min, YH
    BLOOD, 2005, 106 (11) : 231B - 231B
  • [4] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [5] Mylotarg, fludarabine, ara-C and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [6] Adaptive randomization of idarubicin and Ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute Myelogenous leukemia (AML) or high-risk Myelodysplastic syndrome (MDS)
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, R
    Giles, F
    BLOOD, 2002, 100 (11) : 264B - 264B
  • [7] Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    Cortes, J
    Estey, E
    Beran, M
    O'Brien, S
    Giles, F
    Koller, C
    Keating, M
    Kantarjian, H
    LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) : 479 - 484
  • [8] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [9] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 615A - 615A
  • [10] Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS).
    Yee, KWL
    Cortes, J
    Garcia-Manero, G
    Verstovsek, S
    Ferrajoli, A
    Wierda, WG
    Thomas, D
    Faderl, S
    King, I
    O'Brien, SM
    Sznol, M
    Giles, FJ
    BLOOD, 2005, 106 (11) : 311B - 311B
12345